EUVIMEDEUVIMED entdecken
Crossref

Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy

Yumin Huang, Guizhen Cheng, Xin Tang, Zhiming Chen, Cheng Zhang, Jiankang Hu, Xiaoshan Chen, Jun Wang, Zhaoming Chen, Mohan Zhao, Jinsong Liu, Tingting Xu iD und 5 weitere

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c02858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Yumin Huang und 16 weiteren Autor:innen. Beteiligte Einrichtung: China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Provincial Key Laboratory of Biocomputing, Institute of Drug Discovery, Guang…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Transcription Factors, Drug Discovery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRD9, a unique component of the ncBAF complex, has emerged as a promising therapeutic target in various cancers such as synovial sarcoma (SS) and acute myeloid leukemia (AML). Herein, we report the design, synthesis, and biological evaluation of BRD9 PROTACs based on diverse cereblon-binding ligands. Through structure-activity study, we identified 32 (XYD270) as a highly potent PROTAC demonstrating excellent degradation activity in HS-SY-II cells (DC50 = 0.082 nM, Dmax = 96%) and MV4;11 cells (DC50 = 3.9 nM, Dmax = 90%). Notably, 32 displayed robust antiproliferative activity in MV4;11 cells (IC50 = 50 nM) and HS-SY-II cells (IC50 = 1.65 μM). In an MV4;11 xenograft model, once-daily administration of 32 (10 mg/kg) achieved significant tumor growth inhibition (TGI = 54%). Taken together, our findings establish 32 as a promising BRD9 PROTAC with compelling preclinical efficacy in SS and AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsTranscription FactorsDrug DiscoveryHumansAnimalsProteolysis Targeting ChimeraBromodomain Containing ProteinsCell Line, TumorStructure-Activity RelationshipCell ProliferationMiceAdministration, OralXenograft Model Antitumor AssaysFemale

Substanzen

Proteolysis Targeting ChimeraBromodomain Containing ProteinsAntineoplastic AgentsBRD9 protein, humanTranscription Factors

Autor:innen und Institutionen

  • China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Provincial Key Laboratory of Biocomputing, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences…
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • Institute of Health Sciences and Technology, Institutes of Physical Science and Information Technology, Anhui University, Hefei 230601, China.
  • GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou 511436, China.
  • Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education Shenyang Pharmaceutical University, Shenyang 110016, China.
  • Guangdong Provincial Key Laboratory of Biocomputing, Center for Biomedical Digital Science, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.

ORCID-Profile: Tingting Xu, Yan Zhang, Bin Lin, Yong Xu

Förderung

  • National Key Research and Development Program of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
  • Guangzhou Municipal Science and Technology Project
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences
  • Guangdong Province Grant for Belt and Road Joint Laboratory

Zitieren

APA

Huang, Y., Cheng, G., Tang, X., Chen, Z., Zhang, C., Hu, J., Chen, X., Wang, J., Chen, Z., Zhao, M., Liu, J., Xu, T., Ma, J., Zhang, Y., Lin, B., Shen, H., & Xu, Y. (2026). Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02858

Vancouver

Huang Y, Cheng G, Tang X, Chen Z, Zhang C, Hu J, et al. Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02858

BibTeX
@article{Huang2026,
  author = {Huang, Yumin and Cheng, Guizhen and Tang, Xin and Chen, Zhiming and Zhang, Cheng and Hu, Jiankang and Chen, Xiaoshan and Wang, Jun and Chen, Zhaoming and Zhao, Mohan and Liu, Jinsong and Xu, Tingting and Ma, Jinming and Zhang, Yan and Lin, Bin and Shen, Hui and Xu, Yong},
  title = {Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c02858}
}
Kostenlos starten →